

WE CLAIM:

1. A method for treating alopecia or promoting hair growth in an animal, which comprises administering to said animal an effective amount of a heterocyclic ester or amide.


2. The method of claim 1, wherein the heterocyclic ester or amide is non-immunosuppressive.

3. The method of claim 1, wherein the heterocyclic ester or amide has an affinity for an FKBP-type immunophilin.

4. The method of claim 3, wherein the FKBP-type immunophilin is FKBP-12.

5. The method of claim 1, wherein the heterocyclic ester or amide is a compound of formula

I



I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A and B, together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO₂, N, NH, or NR₁ heteroatom;

X is O or S;

Z is O, NH, or NR₁;

W and Y are independently O, S, CH₂, or H₂;

R₁ is C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar₁)_n, C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl substituted with (Ar₁)_n, C₃-C₆ cycloalkyl, C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl substituted with C₃-C₆ cycloalkyl, and Ar₂;

n is 1 or 2;

R₂ is either C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₃-C₆ cycloalkyl, C₆-C₇ cycloalkenyl or Ar₁, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C₁-C₄ straight or branched chain alkyl,


C₂-C₄ straight or branched chain alkenyl, and hydroxy; and

Ar₁ and Ar₂ are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

6. The method of claim 5, wherein the mono- or bicyclic, carbo- or heterocyclic ring is selected from the group consisting of naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, and phenyl.

7. The method of claim 5, wherein the one or more additional heteroatom(s) in the 5-7 membered saturated or unsaturated heterocyclic ring is NH or NR₁.

8. The method of claim 1, wherein the heterocyclic ester or amide is a compound of formula II



II

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A, B and C are independently CH_2 , O, S, SO, SO_2 , NH, or NR_1 ;

R_1 is C_1 - C_6 straight or branched chain alkyl or C_2 - C_6 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of $(\text{Ar}_1)_n$ and C_1 - C_6 straight or branched chain alkyl or C_2 - C_6 straight or branched chain alkenyl substituted with $(\text{Ar}_1)_n$;

n is 1 or 2;

R_2 is either C_1 - C_6 straight or branched chain alkyl, C_2 - C_6 straight or branched chain alkenyl, C_3 - C_6 cycloalkyl, C_3 - C_6 cycloalkenyl, or Ar_1 ; and

Ar_1 is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one

or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

9. The method of claim 8, wherein:

A is CH₂;

B is CH₂ or S;

C is CH₂ or NH;

R₁ is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl; and

R₂ is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, and tert-butyl.

10. The method of claim 9, wherein:

B is CH₂;

C is NH; and

R₁ is 3-phenylpropyl.

11. The method of claim 9, wherein:

B is S; and

C is CH₂.


12. The method of claim 8, wherein the compound is selected from the group consisting of:

3-phenyl-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine)carboxylate;

3-(3-pyridyl)-1-propyl (2S)-1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate; and

pharmaceutically acceptable salts, esters, and solvates thereof.

13. The method of claim 1, wherein the heterocyclic ester or amide is a compound of formula III



III

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A, B, C and D are independently CH_2 , O, S, SO, SO_2 , NH, or NR_1 ;

R_1 is C_1 - C_8 straight or branched chain alkyl or C_2 - C_8 straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of

(Ar₁)_n and C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl substituted with (Ar₁)_n;

n is 1 or 2;

5

R₂ is either C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₃-C₆ cycloalkyl, C₅-C₆ cycloalkenyl, or Ar₁; and

10

Ar₁ is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₆ alkoxy, C₂-C₆ alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

15

20

14. The method of claim 13, wherein:

A is CH₂;

B is CH₂;

C is S, O or NH;

25

D is CH₂;

R₁ is selected from the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl; and

R₂ is selected from the group consisting of 1,1-


dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5-trimethoxyphenyl.

15. The compound of claim 14, wherein:

C is NH; and

R₂ is 1,1-dimethylpropyl or phenyl.

16. The method of claim 1, wherein the heterocyclic ester or amide is a compound of formula IV



IV

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

V is C, N, or S;

A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO₂, N, NH, and NR;

R is either C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, C₃-C₉,

Ar₁ and Ar₄ are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring; wherein the individual ring size is 5-8 members; wherein said heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S; and

R_1 , R_2 , W , X , Y , and Z are as defined in claim 5 above.

17. A pharmaceutical composition which comprises:

- (i) an effective amount of a heterocyclic ester or amide for treating alopecia or promoting hair growth in an animal; and
- (ii) a pharmaceutically acceptable carrier.

18. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide is non-immunosuppressive.


A2

19. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide has an affinity for an FKBP-type immunophilin.

5 20. The pharmaceutical composition of claim 19, wherein the FKBP-type immunophilin is FKBP-12.

Para 13

21. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide is a compound of formula I



15

20 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

25 A and B, together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to the nitrogen atom, one or more additional O, S, SO, SO₂, N, NH, or NR₁ heteroatom;

X is O or S;

Z is O, NH, or NR₁;

W and Y are independently O, S, CH₂, or H₂;

R₁ is C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar₁)_n, C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl substituted with (Ar₁)_n, C₃-C₆ cycloalkyl, C₁-C₆ straight or branched chain alkyl or C₂-C₆ straight or branched chain alkenyl substituted with C₃-C₆ cycloalkyl, and Ar₂;

n is 1 or 2;

R₂ is either C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₃-C₆ cycloalkyl, C₅-C₇ cycloalkenyl or Ar₁, wherein said alkyl, alkenyl, cycloalkyl or cycloalkenyl is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of C₁-C₄ straight or branched chain alkyl, C₂-C₄ straight or branched chain alkenyl, and hydroxy; and

Ar₁ and Ar₂ are independently an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄

alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

5

22. The pharmaceutical composition of claim 21, wherein the mono- or bicyclic carbo- or heterocyclic ring is selected from the group consisting of naphthyl, indolyl, furyl, thiazolyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, fluorenyl, and phenyl.


10

23. The pharmaceutical composition of claim 21, wherein the one or more additional heteroatom(s) in the 5-7 membered saturated or unsaturated heterocyclic ring is NH or NR₁.

15

24. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide is a compound of formula II

20



II

25

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A, B and C are independently CH_2 , O, S, SO, SO_2 , NH, or NR_1 ;

R_1 is $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or $\text{C}_2\text{-C}_6$ straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of $(\text{Ar}_1)_n$ and $\text{C}_1\text{-C}_6$ straight or branched chain alkyl or $\text{C}_2\text{-C}_6$ straight or branched chain alkenyl substituted with $(\text{Ar}_1)_n$;

n is 1 or 2;

R_2 is either $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, $\text{C}_2\text{-C}_6$ straight or branched chain alkenyl, $\text{C}_3\text{-C}_6$ cycloalkyl, $\text{C}_5\text{-C}_7$ cycloalkenyl, or Ar_1 ; and

Ar_1 is a an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, $\text{C}_1\text{-C}_6$ straight or branched chain alkyl, $\text{C}_2\text{-C}_6$ straight or branched chain alkenyl, $\text{C}_1\text{-C}_6$ alkoxy, $\text{C}_2\text{-C}_6$ alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

25. The pharmaceutical composition of claim 24, wherein:

A is CH_2 ;

B is CH_2 or S;

C is CH_2 or NH;

5 R_1 is selected from the group consisting of 3-phenylpropyl and 3-(3-pyridyl)propyl; and

R_2 is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, and tert-butyl.

10 26. The pharmaceutical composition of claim 25, wherein:

B is CH_2 ;

C is NH; and

R_1 is 3-phenylpropyl.

15 27. The pharmaceutical composition of claim 25, wherein:

B is S; and


C is CH_2 .

20 28. The pharmaceutical composition of claim 24, wherein the compound is selected from the group consisting of:

3-phenyl-1-propyl (2S) -1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate;

25 3-(3-pyridyl)-1-propyl (2S) -1-(3,3-dimethyl-1,2-dioxopentyl)-2-(4-thiazolidine) carboxylate; and
pharmaceutically acceptable salts, esters, and solvates thereof.

29. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide is a compound of formula III



III

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

A, B, C and D are independently CH₂, O, S, SO, SO₂, NH, or NR₁;

R₁ is C₁-C₅ straight or branched chain alkyl or C₂-C₅ straight or branched chain alkenyl, which is substituted with one or more substituent(s) independently selected from the group consisting of (Ar₁)_n and C₁-C₅ straight or branched chain alkyl or C₂-C₅ straight or branched chain alkenyl substituted with (Ar₁)_n;

n is 1 or 2;

R₂ is either C₁-C₅ straight or branched chain alkyl, C₂-C₅ straight or branched chain alkenyl, C₃-C₅ cycloalkyl, C₃-C₅ cycloalkenyl, or Ar₁; and

Ar₁ is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein the ring is either unsubstituted or substituted with one

5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995

or more substituent(s) independently selected from the group consisting of halo, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, and amino; wherein the individual ring size is 5-6 members; and wherein the heterocyclic ring contains 1-6 heteroatom(s) independently selected from the group consisting of O, N, and S.

30. The pharmaceutical composition of claim 29, wherein:

A is CH₂;

B is CH₂;

C is S, O or NH;

D is CH₂;

R₁ is selected from the group consisting of 3-phenylpropyl and (3,4,5-trimethoxy)phenylpropyl; and

R₂ is selected from the group consisting of 1,1-dimethylpropyl, cyclohexyl, tert-butyl, phenyl, and 3,4,5-trimethoxyphenyl.


31. The compound of claim 30, wherein:

C is NH; and

R₂ is 1,1-dimethylpropyl or phenyl.

32. The pharmaceutical composition of claim 17, wherein the heterocyclic ester or amide is a compound

of formula IV



or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:

V is C, N, or S;

A and B, taken together with V and the carbon atom to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing, in addition to V, one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO₂, N, NH, and NR;

R is either C₁-C₃ straight or branched chain alkyl, C₂-C₃ straight or branched chain alkenyl, C₃-C₆ cycloalkyl, C₃-C₇ cycloalkenyl, or Ar₁, wherein R is either unsubstituted or substituted with one or more substituent(s) independently selected from the group consisting of halo, haloalkyl, carbonyl, carboxy, hydroxy, nitro, trifluoromethyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl, C₁-C₄ alkoxy, C₂-C₄ alkenyloxy, phenoxy, benzyloxy, thioalkyl, alkylthio, sulfhydryl, amino, alkylamino, aminoalkyl, aminocarboxyl, and Ar₄;

5

Y,